Inside the Digital Health Disruption: A Conversation with Dr. Priya Venkataraman on Market Research in Healthcare's New Era
Introduction: Meeting the Expert
Dr. Priya Venkataraman is a Principal Research Director specializing in healthcare and life sciences market intelligence, with over 18 years of experience spanning pharmaceutical competitive intelligence, medical device adoption research, and digital health consumer behavior. She has led research programs for three of the top ten global pharmaceutical companies and advises multiple digital health startups on go-to-market strategy. We spoke with her about the seismic shifts reshaping healthcare market research and what practitioners need to know to stay relevant.
"Healthcare market research used to be about understanding what physicians prescribed and why. Today, it's about mapping an entirely new ecosystem where patients, payers, providers, regulators, and technology platforms all have veto power over any given commercial outcome." — Dr. Priya Venkataraman
The Scale of the Healthcare Market Opportunity
Let's start with the big picture. How large and how fast is the healthcare market growing, and what does that mean for researchers?
The numbers are genuinely staggering, and I think people who don't work in healthcare often underestimate how dominant this sector is becoming in the global economy. Global healthcare expenditure crossed $10 trillion in 2022 and is expected to reach approximately $15 trillion by 2030, growing at a CAGR of around 5.4%. The digital health segment within that is growing much faster — estimates from Grand View Research put the global digital health market at $211 billion in 2022 with a projected CAGR of 18.6% through 2030.
What that means practically for market researchers is that the addressable market for healthcare intelligence has never been larger, but neither has the complexity of the questions we're being asked to answer. A pharma company launching a new oncology therapy isn't just asking "what do oncologists think?" They're asking how reimbursement pathways will affect formulary access, how patient advocacy communities will respond, whether digital companion apps will drive adherence, and how real-world evidence platforms will shape prescribing behavior over the product lifecycle. These are multi-year, multi-stakeholder, multi-methodology research questions.
Navigating the Regulatory and Ethical Landscape
Healthcare research operates under a uniquely complex regulatory and ethical framework. How does that shape methodology choices?
Profoundly, and this is where healthcare research diverges most sharply from consumer goods or financial services research. We operate under a web of regulations — HIPAA and HITECH in the United States governing patient data privacy, GDPR and its healthcare-specific provisions in Europe, FDA guidelines on communication with healthcare professionals, and industry codes like the EFPIA Code of Practice in Europe and PhRMA Code in the U.S. that govern how pharmaceutical companies can engage with physicians in research contexts.
What this means practically is that our recruitment processes, consent frameworks, data storage architectures, and reporting protocols must be designed by specialists who understand these constraints, not just research generalists. One thing I see frequently is boutique research firms winning healthcare contracts based on price and then discovering mid-project that their standard panel recruitment processes are non-compliant with HCP engagement guidelines. That is an expensive and reputationally damaging mistake.
On the positive side, the regulatory infrastructure around real-world data is evolving rapidly. The FDA's Real-World Evidence Framework and the EMA's parallel initiatives are creating pathways for researchers to use de-identified claims data, electronic health record data, and patient registry data in ways that generate evidence far richer than any survey could produce. Platforms like IQVIA's Real-World Insights, Komodo Health, and Veeva Vault are becoming as central to healthcare market research as traditional panel providers.
The Patient as a Research Stakeholder
How has the patient voice changed in healthcare market research over the past decade?
This is one of the most important transformations I've witnessed in my career. When I started in this field, patient research was largely an afterthought — a box-ticking exercise that happened after the physician and payer research was complete. Today, in most serious healthcare market research programs, the patient perspective is a foundational input that shapes everything from clinical trial design to commercial launch sequencing.
Several forces are driving this. Regulatory bodies including the FDA's Patient-Focused Drug Development initiative and the EMA's patient engagement framework now formally require that patient experience data inform drug approval processes. This has created institutional pressure on pharma companies to develop genuine capabilities in patient insight generation, not just advisory board theater.
Simultaneously, the rise of digital patient communities — platforms like PatientsLikeMe, Inspire, and disease-specific Facebook groups with memberships in the hundreds of thousands — has created rich passive data sources that allow researchers to understand the lived experience of disease at scale and in authentic, unprimed contexts. Social listening in healthcare requires specialized tools like Treato or Medimix that are trained on medical terminology and can appropriately filter for adverse event reporting obligations.
The challenge is that patient populations are not homogeneous, and healthcare researchers must be especially careful about representativeness. Digital health communities skew younger, more educated, and more engaged than the broader patient population — a sampling bias that can significantly distort insights if not corrected for.
Digital Health and the New Adoption Research Agenda
Digital health — wearables, telehealth, AI diagnostics, digital therapeutics — is growing explosively. What are the specific research challenges in this space?
Digital health is simultaneously the most exciting and most treacherous area to research right now. The product categories are genuinely novel, which means there is limited validated secondary research to anchor primary work, and both clinicians and patients are on steep learning curves that make stated preferences highly unstable.
Take digital therapeutics as an example. Companies like Pear Therapeutics — which, despite its 2023 bankruptcy, pioneered the prescription digital therapeutic model — were operating in a space where neither physicians nor patients nor payers had a stable mental model for the product category. Research that asked "would you prescribe a digital therapeutic for substance use disorder?" was measuring something closer to imagination than actual intention, because the clinical decision-making context simply didn't exist yet in respondents' experience.
The most effective research approaches in emerging digital health categories tend to be sequential: start with deep qualitative exploration to map existing mental models and identify the key barriers and enablers, then design quantitative work that tests specific product configurations and value propositions rather than abstract category acceptance. Conjoint analysis and discrete choice experiments are particularly valuable here, because they force respondents to make realistic trade-offs between features, price points, and clinical evidence requirements rather than expressing unconstrained enthusiasm for a technology they've never encountered.
For telehealth adoption specifically, the post-pandemic normalization data is fascinating. McKinsey's 2023 Consumer Health Insights Survey found that telehealth utilization has stabilized at approximately 13–17% of outpatient visits — significantly above pre-pandemic levels but well below the 2020 peak. Understanding which patient segments, condition types, and geographic contexts drive sustained telehealth adoption versus reversion to in-person care is a rich segmentation research question that will occupy the sector for years.
The Future of Healthcare Market Research
What skills and capabilities do you think are most important for healthcare market researchers to develop over the next five years?
Three things stand out clearly to me. First, data science and analytics fluency. The healthcare data ecosystem — real-world evidence, claims data, genomic data, sensor data from wearables — is generating research-grade intelligence at a volume and velocity that traditional survey-and-IDI methodologies simply cannot match. Researchers who can work fluidly across primary and secondary data sources, and who can communicate statistical findings to non-technical stakeholders, will command a significant premium.
Second, genuine clinical literacy. The best healthcare market researchers I know can read a Phase III clinical trial design critically, understand the implications of a PDUFA date, and explain why a particular HEOR model matters to a market access team. This knowledge doesn't come from a research methodology course — it comes from sustained immersion in the sector and deliberate education through resources like the ISPOR guidelines on value evidence frameworks and clinical practice guidelines from bodies like NICE or ASCO.
Third, and perhaps most importantly, ethical judgment in AI-augmented research contexts. We are already seeing AI being used to synthesize patient forum data, generate synthetic patient populations for modeling, and automate qualitative coding of interview transcripts. These applications offer genuine efficiency gains, but they also carry risks — of bias amplification, of privacy erosion, of insight generation that outpaces our ethical frameworks. Healthcare researchers have a particular responsibility here, given the vulnerability of the populations we study and the high-stakes decisions our research informs.
Dr. Venkataraman's research practice is based in Boston and she serves on the advisory board of the Healthcare Market Research Association (HMRA).